about
Claudin-1, -3 and -4 proteins and mRNA expression in benign and malignant breast lesions: a research studyPathological work-up of sentinel lymph nodes in breast cancer. Review of current data to be considered for the formulation of guidelines.[Role of osteopontin in the formation of microcalcifications in breast cancer].MicroRNA expression profiling in benign (sporadic and hereditary) and recurring adrenal pheochromocytomas.The potential prognostic value of connexin 26 and 46 expression in neoadjuvant-treated breast cancerThe CIN4 chromosomal instability qPCR classifier defines tumor aneuploidy and stratifies outcome in grade 2 breast cancer.Extracellular matrix components in breast carcinomas.Discrepancies in current practice of pathological evaluation of sentinel lymph nodes in breast cancer. Results of a questionnaire based survey by the European Working Group for Breast Screening Pathology.The role of radiotherapy in the conservative treatment of ductal carcinoma in situ of the breast.The prognostic significance of tumour-stroma ratio in oestrogen receptor-positive breast cancer.Primary systemic therapy in breast cancer--an update for gynecologic oncologists.Traumatic arterial damage after fine-needle aspirational cytology in mammary complex sclerosing lesions.Syndecan-4 promotes cytokinesis in a phosphorylation-dependent manner.beta-catenin expression and claudin expression pattern as prognostic factors of prostatic cancer progression.Distinction of isolated tumour cells and micrometastasis in lymph nodes of breast cancer patients according to the new Tumour Node Metastasis (TNM) definitions.Validation of clinical prediction rules for a low probability of nonsentinel and extensive lymph node involvement in breast cancer patients.Tenascin expression in primary and recurrent breast carcinomas and the effect of tenascin on breast tumor cell cultures.Expression of tight junction protein claudin-4 in basal-like breast carcinomas.[Pathologic diagnosis and histopathology record of breast cancer].[Comparison of breast cancer in young and old women based on clinicopathological features].Prognostic potential of ERG (ETS-related gene) expression in prostatic adenocarcinoma.[Immunohistochemical phenotype of breast carcinomas predicts the effectiveness of primary systemic therapy].The influence of expertise of the surgical pathologist to undergrading, upgrading, and understaging of prostate cancer in patients undergoing subsequent radical prostatectomy.A 3-gene proliferation score (TOP-FOX-67) can re-classify histological grade-2, ER-positive breast cancers into low- and high-risk prognostic categories.Primary systemic therapy (PST) of locally advanced breast cancer using Doxorubicin/Docetaxel combination.Lymphoepithelioma-like carcinoma of the breast: not Epstein-Barr virus-, but human papilloma virus-positive.Differences in the expression of histamine-related genes and proteins in normal human adrenal cortex and adrenocortical tumors.[MicroRNA-profiling in breast- and salivary gland-derived adenoid cystic carcinomas].Cutaneous mast cell tumour within a lipoma in a boxer.Secondary tumoural valvulopathy in a dog.Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era.[Combined surgery and radiotherapy in the treatment of ductal carcinoma in situ of the breast: preliminary results of the Hungarian multicenter prospective randomised study].Distribution pattern of the Ki67 labelling index in breast cancer and its implications for choosing cut-off values.[Simplified, low-cost gene expression profiling for the prediction of outcome in breast cancer based on routine histologic specimens].[The results of cetuximab treatment of a patient with multiple pretreated, irinotecan resistant metastatic colorectal cancer].Consistency of staining and reporting of oestrogen receptor immunocytochemistry within the European Union--an inter-laboratory study.Difficulties in the diagnosis of intracystic tumors of the female breast.Claudin-5 protein is a new differential marker for histopathological differential diagnosis of canine hemangiosarcoma.Expression and localisation of claudin-1, -2, -3, -4, -5, -7 and -10 proteins in the normal canine mammary gland.Divergences in diagnosing nodular breast lesions of noncarcinomatous nature.
P50
Q24797635-E75F34C0-DA39-4157-9D6D-068795F5FED6Q30814926-085C5C37-8197-494D-9C37-2479F54E4C31Q30844027-69B7E361-5DA5-4674-A925-38FBB766269BQ34136208-4953450F-06C4-45E4-84DB-21B1941A605DQ34572215-6D86EFD0-3C3E-4B97-96EE-A84683F2F258Q34611524-30BB690F-22D9-431A-A57E-CAEBCF2AED37Q34706675-E3C05C76-D7AD-4E0F-A316-63F8DDC2E313Q35587753-BCB39993-51D7-43FE-B408-0DBD3109F49FQ37148397-9E476909-0320-4DE9-8D07-77A47E5832F8Q37681755-06F1C073-972B-449D-951D-937E3ECE94B3Q37984050-3B764C79-E3A0-4D41-AC07-23FDB47C4DA7Q38479196-49987D73-FC77-4763-B801-00BBC000182CQ39727738-2F6768FD-33A6-4211-9F6E-3116A0B50738Q39940075-D3A2C802-8044-4BC3-ABCE-3A0B01AE0098Q39963410-37F3D412-F2D1-4B11-9852-EC8ECF55B4FEQ40184232-2EEF7E26-A93D-4B96-A0B4-F3CA24E4B3EAQ40848815-AC330EC8-A3DC-4994-AD4A-47DCC449BF94Q42440831-C56364A5-CA82-4A11-AD9F-72CC7516F2E3Q42876573-9C33F2E2-DBF2-4DD9-BDEC-55B84EB74F0EQ43115627-BF1D58DA-7A1C-418E-9AC0-AAD8F84F8D34Q43117102-181A0D8E-4D48-4C74-9898-E4AC974911AFQ43195333-E3409E96-5FC0-46D7-A3B4-76380ED8277DQ43561673-D64C1B71-AC78-41EB-BF05-D9DD98EF1A98Q43627028-12DB3785-7F8D-46E6-9909-4ABC60177BA8Q44554091-467C3917-A753-43CE-B2B2-5A805CD15E34Q45397680-2459A393-827F-4D73-AFCE-EB88E3A32586Q45638015-03072EB9-244F-4128-8D75-341685FA8183Q45913563-0BE170C1-A48E-44F6-AD2B-D306A68FC12BQ45936768-00FF414B-93D9-4CC4-B73D-3B3DA99D833DQ46003465-616E85BC-FF6A-41F4-99B8-9993E4A3695BQ46295120-0B91C7BE-B828-47F6-9DF7-6B6B570611D3Q46323159-DBC5B9F0-DB25-4177-9DC8-74BDDBE61508Q46794306-41595065-AE45-4307-BF13-9D9C4EF5C3EFQ46934740-64C53BBD-92F0-4D19-B1B2-7297DD9DC82AQ46976455-DE01A161-C71C-4633-9099-5C9B8B6073A1Q47280628-4C35986A-265A-4BE6-B974-9134905DE177Q47291892-51282431-2DE5-4882-9073-2306D29C64B8Q47710228-9D5B88DC-5A2A-4E7F-9802-78C2E7CFC3ADQ48514716-2CCB13C5-08BE-42BB-8A29-7EABE68FD75FQ48695792-734CCB73-43F1-409D-89A9-FA3889D9CE56
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Janina Kulka
@ast
Janina Kulka
@en
Janina Kulka
@es
Janina Kulka
@nl
Janina Kulka
@sl
type
label
Janina Kulka
@ast
Janina Kulka
@en
Janina Kulka
@es
Janina Kulka
@nl
Janina Kulka
@sl
prefLabel
Janina Kulka
@ast
Janina Kulka
@en
Janina Kulka
@es
Janina Kulka
@nl
Janina Kulka
@sl
P106
P21
P31
P496
0000-0001-8884-8337